Scientometrics
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4489-4505
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4489
Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective
Xu Feng, Yi-Han Chai, Ke-Xin Jiang, Wen-Bin Jiang, Wen-Chao Chen, Yu Pan
Xu Feng, Yi-Han Chai, Ke-Xin Jiang, Wen-Bin Jiang, Wen-Chao Chen, Yu Pan, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
Co-first authors: Xu Feng and Yi-Han Chai.
Co-corresponding authors: Wen-Chao Chen and Yu Pan.
Author contributions: Feng X and Jiang KX were responsible for conceptualization; Chai YH and Pan Y were responsible for methodology; Jiang KX and Feng X were responsible for investigation; Pan Y, Feng X and Chai YH were responsible for visualization; Chen WC, Jiang WB and Feng X were responsible for supervision; Feng X and Chen WC were responsible for writing – original draft; Pan Y, Feng X and Jiang WB were responsible for writing – review & editing. Feng X and Chai YH are listed as co-first authors for their contributions to both the research and the manuscript. They share responsibility as well as accountability for the work delivered and the research that has been conducted, including substantial contributions to the conception or design of the work, drafting the work or revising it critically for important intellectual content, final approval of the version to be published, and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Chen WC and Pan Y are listed as co-corresponding authors for their contributions to this manuscript. They have read and agreed to the published version of the manuscript, ensuring that all aspects of the work are accurately represented and that all conditions for authorship are met.
Supported by the Zhejiang Provincial Medical and Health Science and Technology Program, No. 2024KY1109.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yu Pan, MD, Physiotherapist, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Qingchun East Road, Shangcheng District, Hangzhou 310016, Zhejiang Province, China. panyu1013@zju.edu.cn
Received: June 4, 2024
Revised: August 24, 2024
Accepted: September 27, 2024
Published online: November 15, 2024
Processing time: 142 Days and 19.9 Hours
Core Tip

Core Tip: Breast cancer gene (BRCA)1 and BRCA2 mutations affect 4%-7% of pancreatic cancer patients and influence their response to therapies such as platinum chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib. A bibliometric analysis of 196 publications highlights growing global research interest, with China and the United States leading. The key contributors include O'Reilly EM's team and Memorial Sloan-Kettering, whereas the Journal of Clinical Oncology stands out for citations. Future trends point toward increased use of PARP inhibitors and combination therapies, offering valuable insights for advancing olaparib research in pancreatic cancer.